Ronak Patel

  In the present investigation an attempt was made to formulate fast dissolving tablets using BCS class II drug Repaglinide, ie low solubility and high permeability to form an inclusion complex to improve the dissolution rate, thus enhancing the bioavailability. Beta-CD inclusion complex was made in varying ratios 1:1, 1:3 and 1:5 of drug and polymer by solvent evaporation method. The complexes were evaluated for phase solubility, drug content and drug release. Phase solubility study revealed AL type indicating linear increase in solubility with increase in the carrier concentrations. The inclusion complex 1:1 ratio prepared by spray dried was studied for drug content uniformity which was ranging from 85-98%, FTIR showed no any compatibility of the drug and beta-CD; DSC and XRD showed distinct loss of drug crystallinity accounting for enhancement in the dissolution rate. SEM revealed spherical shape of the inclusion complex. The drug release study was carried out in 0.1N HCL using USP type paddle dissolution apparatus revealed to be 93% within 5 mins. The FDT was formulated by direct compression method six batches of tablets were prepared with varying ratios of superdisintegrants (F1-F6). The tablets were evaluated for hardness, friability, weight variation, disintegration which was found within the official range, drug content ranging from 89-94%. The formulation F3 containing Crosspovidone was optimized which showed maximum drug release of 98% within 10 mins. Kinetics of drug release from all the tablets followed zero order release with non-Fickian type diffusion. Key words: Repaglinide, Beta- Cyclodextrin, Spray drying and fast dissolving tablets

SLN’s are colloidal carriers developed in the 1990s as an alternative system to the existing traditional carriers (emulsions, liposomes, and polymeric nanoparticles)1. Nanoparticles made from solid lipids are attracting major attention as novel colloidal drug carrier for various applications as they have been proposed as an alternative particulate carrier system. The SLNS are submicron colloidal carriers (50-1000 nm) which are composed of physiological lipid, dispersed in water or in an aqueous surfactant solution2.SLNs are particles consisting of a matrix made from solid lipids. In aqueous dispersion they are stabilised by surfactants or polymers. They consist of a solid matrix protecting incorporated active substances against chemical degradation and providing high flexibility to modify release profiles. The SLN combine the advantages (e.g. physical stability, protection of incorporated labile drugs from degradation, controlled release, excellent tolerability, and scalability to large-scale preparations, excellent biocompatibility) of other traditional colloidal systems3.